Atlanta

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• High blood pressure2 trials
• Amyloidosis1 trial
• Chronic kidney disease1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Narcolepsy1 trial
• Obesity1 trial
• Sarcoidosis1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 34 trials
• Phase 12 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 2/31 trial

Status

• Recruiting4 trials
• Completed2 trials
• Terminated2 trials
• Active, not recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals5 trials
• Priovant Therapeutics, Inc.2 trials
• Jazz Pharmaceuticals1 trial
• Olema Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

  NCT06978725· Phase 2/3· Priovant Therapeutics, Inc.· Source

  Contact: Clinical Trial Administrator

• Recruiting

  A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  NCT06600321· Phase 1· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Terminated

  A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

  NCT06961266· Phase 1· Jazz Pharmaceuticals· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Terminated

  A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

  NCT05761301· Phase 1/2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source